Providing universal health coverage to the nation’s roughly 10 million citizens, Hungary’s National Health Insurance Fund (OEP) has one of the most comprehensive and complex structures in Europe. The organization’s Head of Pricing Support, Dr. Judit Bidló discusses the current mechanisms governing pharmaceutical reimbursements in Hungary, while also identifying the primary limitations and pressures faced by the system.
As introduction for our readers Judit, can you please provide an overview of OEP's function and scope in Hungary and also describe what you are focusing on now as head of pricing support?
From a drug reimbursement point of view, we have one of the most complex and comprehensive regulatory frameworks in Europe
